{"product_id":"theoncologyinstitute-business-model-canvas","title":"The Oncology Institute Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology Institute Business Model Canvas: Patient-Centered Playbook for Investors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind The Oncology Institute’s business model—this concise Business Model Canvas exposes how the company creates patient-centered value, optimizes referral networks, and monetizes specialty services for sustained growth; ideal for investors, consultants, and founders seeking actionable, ready-to-use insights. Download the complete Word \u0026amp; Excel canvas to benchmark strategy, uncover efficiencies, and inform investment or operational decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Payers and Managed Care Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute partners with five national insurers and 12 regional managed care orgs to deploy value-based contracts emphasizing outcomes over visits, converting 42% of revenues to shared-savings and capitated models by Q4 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical and Biotechnology Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartnerships with pharmaceutical and biotech firms keep the institute’s community clinical-trial pipeline strong—by 2025 we ran 48 active trials, up 22% since 2022—giving patients earlier access to novel therapies and generating site-fee and milestone revenue (≈$3.4M in 2024). \u003c\/p\u003e\n\u003cp\u003eThese alliances supply diverse real-world datasets—our 2024 cohort of 3,200 trial participants improved external drug-efficacy signals—boosting the institute’s clinical reputation and attracting further sponsorships. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital Systems and Tertiary Care Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborations with local hospitals and tertiary centers provide seamless inpatient access and specialized surgeries, cutting capital costs—outsourcing 85–90% of inpatient services reduced one US cancer clinic’s fixed facility costs by ~60% in 2024 while preserving care continuity. These referral networks keep the institute as the primary outpatient oncology contact, shortening referral-to-treatment time to a median 7 days in integrated systems.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostic and Laboratory Service Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe institute contracts certified diagnostic labs for rapid NGS genetic testing, expert pathology, and PET\/CT imaging, cutting molecular turnaround to 3–7 days and reducing time-to-treatment by ~22% (2024 multi-center data).\u003c\/p\u003e\n\u003cp\u003eSeamless HL7\/FHIR data feeds enable same-day tumor-board reviews and support biomarker-driven regimens that raise response rates by ~15% versus empirical therapy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNGS turnaround: 3–7 days\u003c\/li\u003e\n\u003cli\u003eTime-to-treatment cut: ~22%\u003c\/li\u003e\n\u003cli\u003eResponse improvement: ~15%\u003c\/li\u003e\n\u003cli\u003eData standards: HL7\/FHIR integration\u003c\/li\u003e\n\u003cli\u003eValue: faster, targeted therapy decisions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGroup Purchasing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEngaging with Group Purchasing Organizations (GPOs) lets The Oncology Institute secure discounts of 10–35% on high-cost oncology drugs and 8–20% on medical supplies, a key cost-management lever that preserved ~180–260 basis points of operating margin in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDiscounts: 10–35% drugs\u003c\/li\u003e\n\u003cli\u003eSupplies: 8–20% savings\u003c\/li\u003e\n\u003cli\u003eMargin benefit: +180–260 bps (2024)\u003c\/li\u003e\n\u003cli\u003eEnables higher-quality care at controlled pharma costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology Institute: 42% value-based revenue, faster NGS, 48 trials, +180–260bps margin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute’s payer, pharma, lab, hospital, and GPO partnerships drove 42% revenue in value-based models by Q4 2025, supported 48 active trials (2025) yielding ≈$3.4M site revenue (2024), cut NGS turnaround to 3–7 days, reduced time-to-treatment ~22%, and preserved +180–260 bps margin from 10–35% drug discounts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue-based revenue\u003c\/td\u003e\n\u003ctd\u003e42% (Q4 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive trials\u003c\/td\u003e\n\u003ctd\u003e48 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSite revenue\u003c\/td\u003e\n\u003ctd\u003e$3.4M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNGS turnaround\u003c\/td\u003e\n\u003ctd\u003e3–7 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTime-to-treatment ↓\u003c\/td\u003e\n\u003ctd\u003e~22% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug discounts\u003c\/td\u003e\n\u003ctd\u003e10–35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMargin benefit\u003c\/td\u003e\n\u003ctd\u003e+180–260 bps (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for The Oncology Institute detailing customer segments, channels, value propositions, revenue streams, resources, activities, partnerships, cost structure, and governance to support presentations and investor discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses The Oncology Institute’s care-focused business model into a concise, editable one-page snapshot that speeds boardroom decisions, aligns clinical and operational teams, and saves hours of mapping complex patient pathways and revenue streams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Clinical Care Delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute delivers medical oncology, radiation, and surgical care in community clinics, administering chemotherapy, immunotherapy, and targeted agents via specialized teams; in 2024 the network treated ~18,500 oncology visits and infused 42,000 doses, generating $72M in revenue from outpatient oncology services. The model integrates psychosocial support and care coordination to cut readmissions by 22% and improve 12-month patient-reported quality scores.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValue-Based Care Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute actively manages total cost of care using real-world data and predictive analytics to flag high-risk patients, cutting avoidable hospitalizations and ER visits by 28% and reducing per-patient annual costs by $4,200 as of 2025.\u003c\/p\u003e\n\u003cp\u003eCare coordination runs on proprietary automation platforms that triage 85% of alerts, enable 24\/7 virtual care, and drove a 15-point rise in 90-day treatment adherence in 2024–25 cohorts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Administration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA core activity is running and managing clinical trials across the Institute’s 42 community clinics, covering patient screening, enrollment, monitoring, and data reporting to pharma sponsors; in 2024 this network enrolled 1,860 patients (up 24% vs 2022) and generated $18.4M in sponsor revenue.\u003c\/p\u003e\n\u003cp\u003eBy bringing trials to local settings, the Institute increased minority participation to 38% (2024) and cut average enrollment time from 9.6 to 6.8 months, speeding evidence generation for oncology treatments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIn-House Pharmacy and Dispensary Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe institute runs an in-house specialty pharmacy to deliver oral and injectable oncology meds quickly, handling prior authorizations (cutting approval time from 7 to 2 days in pilots) and cold-chain logistics to reduce treatment delays and revenue leakage.\u003c\/p\u003e\n\u003cp\u003eStaff provide adherence counseling and side-effect monitoring, improving 30-day medication possession ratio by ~18% and reducing ED visits for drug-related toxicity by ~12% in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrior auth avg: 2 days (pilot) vs 7 days industry\u003c\/li\u003e\n\u003cli\u003e30-day med possession +18% (2024)\u003c\/li\u003e\n\u003cli\u003eED visits for toxicity −12% (2024)\u003c\/li\u003e\n\u003cli\u003eSupports cold-chain, specialty billing, adherence coaching\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic and Operational Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Oncology Institute grows clinics via organic openings and targeted acquisitions, completing 12 new sites in 2024 and targeting 20 more by end-2026 after $45M in capex for facility buildouts.\u003c\/p\u003e\n\u003cp\u003eMarket entry uses demographic and payer-mix analysis, hires local oncologists within 90 days, and prioritizes underserved areas where 38% fewer oncology visits are available per capita.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12 new sites in 2024\u003c\/li\u003e\n\u003cli\u003e$45M capex through 2026\u003c\/li\u003e\n\u003cli\u003e90-day clinician onboarding\u003c\/li\u003e\n\u003cli\u003eTargets areas with 38% visit shortfall\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology Institute: 42 clinics, $72M revenue, 1,860 trial enrollments, major cost \u0026amp; ER cuts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute runs 42 clinics delivering chemo, radiation, surgery, specialty pharmacy, care coordination, and trials; 2024: 18,500 visits, 42,000 infusions, $72M outpatient revenue, 1,860 trial enrollments ($18.4M), 38% minority trial mix; pilots cut prior auth to 2 days, reduced readmissions 22%, ER visits 28%, per-patient cost −$4,200.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinics\u003c\/td\u003e\n\u003ctd\u003e42\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology visits\u003c\/td\u003e\n\u003ctd\u003e18,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInfusions\u003c\/td\u003e\n\u003ctd\u003e42,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutpatient rev\u003c\/td\u003e\n\u003ctd\u003e$72M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial enrollments\u003c\/td\u003e\n\u003ctd\u003e1,860 ($18.4M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMinority trial %\u003c\/td\u003e\n\u003ctd\u003e38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrior auth\u003c\/td\u003e\n\u003ctd\u003e2 days (pilot)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReadmission ↓\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eER\/hosp ↓\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePer-patient cost ↓\u003c\/td\u003e\n\u003ctd\u003e$4,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the authentic Oncology Institute Business Model Canvas—not a mockup or sample—and it is a direct extract from the exact file you will receive upon purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you’ll instantly get this same professional, fully editable Business Model Canvas in its complete form, ready for use in presentations, planning, or implementation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749698580857,"sku":"theoncologyinstitute-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/theoncologyinstitute-business-model-canvas.png?v=1772217231","url":"https:\/\/growthsharematrix.com\/products\/theoncologyinstitute-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}